Clinical trials: Impulsive Behaviors
Impulsive Aggression Comorbid With ADHD
Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M
An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and Excretion of Radio Labeled SPN-810M in Healthy Adult Male Volunteers
- Trial name
- NCT02023606
- Testing
- SPN-810M
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Opioid Use Disorder
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine
This study is open to people between 18 and 65 years of age with opioid use disorder. Opioid use disorder is also called opioid addiction or opioid dependence.
- Trial name
- NCT06628622
- Testing
- BI 1356225
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard…
- Trial name
- NCT02618434
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 32 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Alcoholism
GSK1521498 Alcohol Interaction Study
The aim of the study is to assess the safety and tolerability of GSK1521498 in combination with alcohol and to determine the amount of GSK1521498 and alcohol in your blood after you have been given these together.
- Trial name
- NCT01366573
- Testing
- GSK1521498
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obsessive-Compulsive Behavior
rTMS Device for Improvement of Obsessive and Compulsive Behaviors
The goal of this investigational study is to evaluate if the treatment using EXOMIND(BTL-699-2) device is able to improve severity of obsessive and compulsive symptoms in adults (aged 22 and older).
- Trial name
- NCT07679750
- Testing
- EXOMIND (BTL-699-2) Active treatment
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.